 Home > Active Ingredient News > Endocrine System > From pharmacology to use, read saxagliptin in one article

From pharmacology to use, read saxagliptin in one article

 Last Update: 2023-02-01
 Source: Internet
 Author: User

Tags

6.25 mg ml

what quillaia extract

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

*For medical professionals only

Evidence-based medicine, rational use of medicine

Satagliptin is a commonly used hypoglycemic drug in clinical practice, what pharmacological effects does it have? What type of patient is it suitable for? How should medication be used? Today we will read an article
.

How much do you know about the pharmacological effects of saxagliptin is dipeptidyl peptidase 4 (DPP4)
Competitive inhibitors, which reduce the rate of inactivation of incretin hormone and increase its blood concentration, thereby reducing fasting and postprandial blood glucose concentrations in patients with type 2 diabetes mellitus in a glucose-dependent manner; Satagliptin also has a bidirectional regulatory effect on islet function, which can promote insulin secretion while inhibiting the secretion of glucagon by pancreatic islet α cells, and reduce glycogenolysis and gluconeogenesis while promoting glucose transport to cells, thereby efficiently regulating blood sugar
.

Who can use saxagliptin?
Satagliptin can not be used in all patients with diabetes because its effectiveness against type 1 diabetes mellitus and diabetic ketoacidosis has not been established, so it cannot be used in patients
with type 1 diabetes or diabetic ketoacidosis.
Currently the drug is intended only for patients with
type 2 diabetes.

For special populations, it is not recommended for pregnant women and children
.
The drug is generally safe for the elderly, but considering that saxagliptin and its active metabolite are partially eliminated by the kidneys, the dose
should be adjusted as appropriate for elderly patients with renal insufficiency.

It is not affected by eating, and the dose is set as this ^[1-4].

The recommended dosage is 5mg/d orally, and the time of taking the drug is not affected
by eating.
In patients with renal insufficiency, patients with glomerular filtration rate (eGFR) ≥ 45 mL/min/1.
73m2 do not need to adjust the dose; Patients with eGFR<45 mL/min/1.
73<b22>m2 (including those with moderate or severe renal insufficiency) should have their dose adjusted to 2.
5 mg/day and given after hemodialysis
.
Patients with impaired liver function do not require dose adjustment
.

More popular drugs in Corey, where to learn?

What is the pharmacological mechanism of saxagliptin?
Who is banned from satagliptin?
How to deal with overdose?

The "evidence-based medicine" module you want is the 👇 dry drug decision assistant

References:

[1] Drug information: Satagliptin tablets, Jiangsu Aosaicom Pharmaceutical Co.
, Ltd.
, Sinopharm H20193009
.

[2] Drug information: Satagliptin tablets, Chia Tai Tianqing Pharmaceutical Group Co.
, Ltd.
, Sinopharm H20203467; 2020/09/08
。

[3] Product Information:ONGLYZA-saxagliptin tablet,film coated,AstraZeneca Pharmaceuticals LP,Updated October 24,2019
。

[4] Product Information:ONGLYZA-saxagliptin tablet,film coated,Cardinal Health,Updated July 31,2021
。

Click "Read Original" for more dry medications

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.